RecruitingPhase 4NCT07270835

Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma

Studying Acquired hemophagocytic lymphohistiocytosis associated with malignant disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
The First Affiliated Hospital of Soochow University
Principal Investigator
Xuefeng He, doctor
department of hematology, The First Affiliated Hospital of Soochow University
Intervention
Rituximab(drug)
Enrollment
40 enrolled
Eligibility
14-80 years · All sexes
Timeline
20252027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07270835 on ClinicalTrials.gov

Other trials for Acquired hemophagocytic lymphohistiocytosis associated with malignant disease

Additional recruiting or active studies for the same condition.

See all trials for Acquired hemophagocytic lymphohistiocytosis associated with malignant disease

← Back to all trials